My name is Andrew Sulaiman and I am a second-year medical student at Kansas City University. Prior to starting medical school, I earned my PhD in Biochemistry from the University of Ottawa, Canada. My research focused on developing novel therapies to target triple-negative breast cancer (TNBC) and its cancer stem cell population. Throughout medical school I have been eager to continue performing research and when I joined the Konorev Lab at Kansas City University, we blended my expertise in TNBC and Dr. Eugene Konorev’s expertise in cardiology research. Together, we developed our current project which is a two-pronged approach to reduce the cardiotoxic effects of doxorubicin, a chemotherapy commonly used on TNBC patients while enhancing its anti-tumor effects via modulation of TGF-β. Medical school has greatly expanded my understanding to the clinical side of oncology. My long-term goal is to work as an oncologist while also conducting research so that I can offer the best care to my patients.